All News
Clinically suspect arthralgias: justified or artefact?
Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.
Read Article
Are T cells the missing link in pre-clinical RA?
T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA.
Read Article
Targeted therapies in Sjogren’s syndrome: are we close?
There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there are no current licensed therapies.
AOSD: Young vs. Elderly Onset AOSDis an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million. https://t.co/bB2mpul3j7 https://t.co/ic6mY04ddF
Links:
Dr. John Cush RheumNow ( View Tweet)
Promising new therapies in SLE
Dr. Yuz Yusof ( @Yuz6Yusof ) weighs in.
The pharmacology treatment in SLE is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians.
https://t.co/cdVw771HDs https://t.co/OYcN8hFLcP
Links:
Dr. John Cush RheumNow ( View Tweet)
An update on JAK inhibitors and cardiovascular risks
Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors.
https://t.co/VovWE2OuXW https://t.co/QXKZLh5RuK
Links:
Dr. John Cush RheumNow ( View Tweet)
Targeted therapies in Sjogren’s syndrome: are we close?
There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there is no current licensed therapies.
https://t.co/B4kKDjhuh7 https://t.co/pGWpSNhJe2
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 – Day 3 Report
https://t.co/qseMZiaHFq https://t.co/pnijisF9Jt
Links:
Dr. John Cush RheumNow ( View Tweet)
Unmasking Lupus Pregnancy: Adherence and Drug Monitoring Dilemmas
Preliminary data from a lupus pregnancy LEGACY cohort presented at #EULAR23 are alarming.
Dr. Bella Mehta ( @bella_mehta ) shares more.
https://t.co/cY2G4s4yR0 https://t.co/isepEb8OXD
Links:
Dr. John Cush RheumNow ( View Tweet)
RA and cancer risk in the biologic era
RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era.
https://t.co/4Pe6SIS6yb https://t.co/e2enjkXoly
Links:
Dr. John Cush RheumNow ( View Tweet)
AI in RA: the story grows along the patient pathway
The use of AI to analyse large data sets using its subset component machine learning (ML) has taken centre stage recently in the management of rheumatic conditions including RA.
https://t.co/Jv4dmV2tlU https://t.co/KkgW0cD1QM
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR23 – Day 2 Report
Day 2 at the international EULAR Congress meeting is always bigger and busier. There are more sessions to choose from and more audience questions in the big auditorium presentations.
https://t.co/vjrG7ez2fX https://t.co/HUuDImzqZA
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR points to consider in the match from PSO to PSA. 5 overarching principles and 10 points to consider. The presence of synovitis in PSO could be used as an outcome for prevention trials, Zabotti A et al, Abst#OP0062 #EULAR2023 @RheumNow https://t.co/tbnuhBCjTU
Dr. Antoni Chan synovialjoints ( View Tweet)
The definition of early axSpA based on expert consensus after going through the Delphi process by ASAS is that the duration of axial symptoms is equal or less than 2 years. Navarro-Compan V, Abst#OP0055 #EULAR2023 @RheumNow https://t.co/5byn0kBEIQ
Dr. Antoni Chan synovialjoints ( View Tweet)
Dual IL-17A/F inhibition with Bimekizumab reduced MRI inflammatory change in the SIJ and spine in AxSpA, and increasing proportion achieving MRI remission at Wk52, Abst#POS0246 #EULAR2023 @RheumNow https://t.co/w4VkkUklGl
Dr. Antoni Chan synovialjoints ( View Tweet)
The International Map of AxSpA (IMAS) of >5k patients: delay mean 7.4+/-9 years, 75% active disease, 60% poor mental health, 21% sick leave, 4.6 GP visits before diagnosis, fear=disease progression, hope=relief of pain, IMAS Abst#POS0298 #EULAR2023 @RheumNow https://t.co/wB9Jtbgvy7
Dr. Antoni Chan synovialjoints ( View Tweet)
Important from @cappelliMD @jhrheumatology irAE cohort on predictors of DMARD requirement in ICI-inflammatory arthritis, and persistent ICI-IA post-ICI cessation.
The better we can predict these patients, the more we can get the right therapy early
POS0951 #EULAR2023 @RheumNow https://t.co/YGTRl71505
David Liew drdavidliew ( View Tweet)
EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ
Dr. Antoni Chan synovialjoints ( View Tweet)
The course of symptoms in CSA to RA showed greater severity in the ACPA+ group compared to the ACPA- group. This correlated with MRI-subclinical joint score, suggesting different underlying processes Khidir S Abst#POS319 #EULAR2023 @RheumNow https://t.co/C2ADAkkSM2
Dr. Antoni Chan synovialjoints ( View Tweet)
Better at Predicting RA from MRI: Humans or Computers?
https://t.co/xRVatfiRKS https://t.co/Gwypq8lcdl
Links:
Dr. John Cush RheumNow ( View Tweet)